Appointed
Douglas Williams
Class I Director
CAMP ·
Camp4 Therapeutics Corp
appointed Douglas Williams, PhD as a Class I director
Ready 8-Ks
21
Latest filing
June 12, 2026, 4:10 PM ET
Top materiality
0.90
Event mix
other_material ×10 · earnings ×6 · leadership ×2
Sentiment
7 pos · 1 neg · 13 neu
Latest earnings
▼ miss 2026-Q1
Executive change
recent →
Recent 8-K filings for CAMP
Highest-materiality recent filing
CAMP4 Therapeutics announces up to $100M private placement and board changes
- Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.
- Second closing of up to $50M contingent on regulatory clearance for SYNGAP1 trial and stock price milestone or waiver.
-
Stockholders approved amendment to 2024 Equity Incentive Plan to include pre-funded warrants in evergreen share calculation.
-
CMP-002 produced statistically significant improvement in seizure threshold and severity in SYNGAP1 haploinsufficient mice.
-
Cash and equivalents $99.2M as of 3/31/26, down from $109.5M; runway expected into 2028.
-
CAMP4 appoints Michael MacLean to Board, effective April 1, 2026
Michael MacLean, former CFO of Avidity Biosciences, joins as Class III director; board expands to 9 members.
-
CAMP4 FY2025 net loss $80.4M; cash runway into 2028, GSK deal, SYNGAP1 progress
Net loss of $80.4M in FY2025 vs $51.8M in FY2024, driven by $29.8M non-cash loss on derivative tranche liability.
-
CAMP4 Therapeutics updates corporate presentation; no specific material changes disclosed
Company furnished an updated corporate presentation as Exhibit 99.1.
-
CAMP4 Therapeutics moves to larger Watertown lab; terminates Cambridge lease early with ~$2.1M fee
New 44,000 sq ft Watertown lease (100 Talcott Ave) through June 2030; base rent $40/sq ft with 3% annual escalations.
-
CAMP4 Therapeutics prices 5M share offering at $6.00, expects $28M net proceeds
CAMP4 Therapeutics priced public offering of 5,000,000 shares of common stock at $6.00 per share.
-
CAMP4 enters collaboration with GSK for ASO therapeutics; $17.5M upfront, up to $440M milestones
Collaboration with GSK to discover ASO therapeutics for neurodegenerative and kidney diseases using CAMP4's RAP Platform.
-
CAMP4 Q3 net loss $15.1M, cash $75.3M; advances CMP-002 with up to $100M placement
Cash, equivalents, and marketable securities $75.3M at Sept 30, up from $39.1M at June 30.
-
CAMP4 initiates GLP toxicology studies for CMP-SYNGAP-01; Phase 1/2 target H2 2026
Initiated GLP toxicology studies for CMP-SYNGAP-01, a regulatory RNA-targeting therapeutic for SYNGAP1-related disorders.
-
CAMP4 Therapeutics announces up to $100M private placement and board changes
Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.
-
CAMP4 reports Q2 net loss of $12.6M; cash $39.1M; pipeline advances in SYNGAP1 and UCD programs
Net loss of $12.6M for Q2 2025, flat vs Q2 2024; R&D expenses $10.3M, G&A $4.2M.
-
CAMP4 Therapeutics annual meeting elects four Class I directors, ratifies EY as auditor
James Boylan elected with 15,802,709 votes for, 900,961 against, 6,002 abstain.
-
CMP-SYNGAP-01 restored SYNGAP1 protein to near-normal in haploinsufficient mice and rescued motor/learning defects.
-
CAMP4 Q1 net loss $12.4M; Phase 1 UCD data Q4 2025; SYNGAP1 candidate nominated
Net loss of $12.4M for Q1 2025, flat YoY; cash, equivalents, and marketable securities $49.3M as of March 31, 2025.
-
CAMP4 reports FY2024 net loss $51.8M; cash $64M, Phase 1 data expected Q4 2025
Net loss of $51.8M for FY2024 vs $49.3M in FY2023; R&D expenses $38.8M, G&A $14.9M.
-
CAMP4 Therapeutics appoints two new directors, expands board to 12 members
Douglas Williams, PhD and Murray Stewart, DM FRCP appointed as Class I and Class II directors, effective 3/17/25.
-
Phase 1 SAD portion completed: 48 healthy volunteers, 32 received CMP-CPS-001; no serious adverse events, no maximum tolerated dose reached.
-
CAMP4 reports Q3 net loss $13.5M, completes IPO raising $82.1M, and signs BioMarin collaboration
Q3 net loss $13.5M vs $11.7M in prior year; R&D $9.7M, G&A $3.8M.
-
Fifth amended charter effective Oct 15, 2024; authorizes 175M shares of common stock and 25M shares of undesignated preferred stock.
Executive changes
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material